News Briefing channel feed

Ideaya part­ners with Gilead; Lil­ly ex­tends of­fer for Point; The­seus lets go of CEO, CMO

15 hours ago

Tharim­mune's pub­lic of­fer­ing; Cul­mi­na­tion Bio rais­es $10M; Pep­per Bio's seed round led by NFX

3 days ago

Flag­ship aims to raise $3B; Phe­nom­ic inks an­oth­er phar­ma deal; On­covi­ta gets €8M for can­cer vac­cine

4 days ago

Lil­ly to pay up to $660M in new deal with PRISM Bi­o­Lab; Boehringer part­ners with Phe­nom­ic AI

5 days ago

Aro rais­es $41M; Can­del’s lay­offs; Lil­ly to ex­pand its ac­cel­er­a­tor to San Diego

6 days ago

As­traZeneca's KRAS deal with Yusen Jian­heng; Abeona gets a PDU­FA date

Last week

Syn­cona buys gene ther­a­py com­pa­ny; Ory­zon’s €45M fi­nanc­ing agree­ment; In­Dex scraps PhI­II drug

Last week

Al­to Neu­ro­science clos­es $45M round; Sim­cere part­ners with Con­nect; Myricx li­cens­es WuXi an­ti­body

Last week

Chiesi’s new li­cens­ing deal with Hais­co; Ox­u­ri­on to file for bank­rupt­cy; Hong Kong CD­MO rais­es $210M

2 weeks ago

Dana­her/Ab­cam deal set to close next month; Cereno's loan; March Bio­sciences to ad­vance its CAR-T in­to PhII

3 weeks ago

Gilde Health­care's €140M; EMD Serono to move US HQ to Boston; Arc­turus up for $35M mile­stone

3 weeks ago

Almi­rall’s new AI deal with Ab­sci; Jazz part­ners with Au­ti­fony; SAB rais­es $67M

3 weeks ago

Teva's new roy­al­ty deal; Se­lec­ta merges with Carte­sian; Vir's he­pati­tis da­ta

3 weeks ago

Vor shares new da­ta for stem cell ther­a­py; Melin­ta part­ners with Ve­na­torx on an­tibi­ot­ic un­der FDA re­view

4 weeks ago

In­tel­lia plans to file IND for AATD tri­al next year; As­cid­i­an rais­es $40M

4 weeks ago

Pyx­is On­col­o­gy lays off 20 em­ploy­ees; Xen­cor’s roy­al­ty sale to a pen­sion plan; Jazz part­ners with MD An­der­son

4 weeks ago

Sage’s PPD drug to cost $15K; Ab­cam share­hold­ers vote 'yes' on Dana­her deal

4 weeks ago

Zen­tal­is shakes up PhI­II plans in ovar­i­an can­cer; Halozyme's deal with Acu­men; Ko­r­ro's $117M pri­vate place­ment

4 weeks ago

Out­look to con­duct an­oth­er tri­al for wet AMD drug; Cara strikes new roy­al­ty deal

Last month

Pro­tag­o­nist's $50M mile­stone; Swiss biotech rais­es $27M; Kymera halts a PhI

Last month

Tonix's de­pres­sion fail; Lil­ly ex­er­cis­es op­tion in Sit­ryx deal; Mil­ner stops fight against Ab­cam ac­qui­si­tion

Last month

Galera con­sid­ers 's­trate­gic' op­tions; No­vo part­ners with French biotech; An­Heart gets $40M

Last month

Vyne aims to raise $88M; Sanofi in­vests in gene ther­a­py com­pa­ny; 4DMT ad­dress­es clin­i­cal hold

Last month

In­tas to pay €42M up­front in Hen­lius deal; Kymera gets $40M mile­stone; Plu­vic­to no longer in short sup­ply

Last month
1234 Next page Last page
A service from the Financial Times